ICAAC 2013: Single-tablet Regimen Improves ART Adherence and Reduces Hospitalization
- Details
- Category: Approved HIV Drugs
- Created on Monday, 23 September 2013 00:00
Antiretroviral treatment that requires only a single tablet taken once-daily were associated with better viral suppression, higher adherence, and lower likelihood of hospitalization, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this month in Denver.
ICAAC 2013: Dolutegravir Shows Good Efficacy Across Patient Groups
- Details
- Category: Approved HIV Drugs
- Created on Monday, 16 September 2013 00:00
The new integrase inhibitor dolutegravir (Tivicay) worked better than boosted darunavir for people starting HIV treatment for the first time, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) last week in Denver. Another study found that dolutegravir worked well across sex, race/ethnicity, and age groups.
ICAAC 2013: New Tenofovir Formulation Has Less Effect on Kidneys and Bones
- Details
- Category: Experimental HIV Drugs
- Created on Friday, 13 September 2013 00:00
Tenofovir alafenamide (TAF), a new formulation that reaches higher levels in cells but allows for lower dosing, was as effective as the current tenofovir disoproxil fumarate (TDF) formulation but had less impact on markers of kidney function and bone turnover, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver.
ICAAC 2013: Researchers Present Data on New NNRTIs AIC292 and MK-1439
- Details
- Category: Experimental HIV Drugs
- Created on Tuesday, 17 September 2013 00:00
A pair of next-generation HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs) demonstrated promising activity in early studies, researchers reported last week at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver. AIC292 showed good antiviral activity in early laboratory, animal and human studies. MK-1439, now in Phase 2b, is likely to interact with ritonavir, but not tenofovir.
ICAAC 2013: CD4 Cell Gene Therapy May Enable Functional Control of HIV Off Treatment
- Details
- Category: Search for a Cure
- Created on Thursday, 12 September 2013 00:00
Two people whose CD4 T-cells were modified to make them resistant to HIV experienced substantial CD4 cell gains and were able to maintain viral suppression after interruption of antiretroviral therapy (ART), according to a late-breaker presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver.
More Articles...
- ICAAC 2013: Tenofovir Vaginal Ring Protects Monkeys on Depo-Provera Against HIV-like Virus
- ICAAC 2013: Many Truvada PrEP Users Are Women and Young People, Survey Finds
- ICAAC 2013: Risk Factors and Screening for HPV Anal Dysplasia
- ICAAC 2013: Raltegravir Safest for HIV+ Patients on Cancer Chemotherapy
- ICAAC 2013: Raltegravir Appears Safe for Mothers and Babies During Pregnancy
- ICAAC 2013: Liver Cancer Often Diagnosed Late with Poor Survival in People with HIV
- ICAAC 2013: Is HCV Infection Increasing Among HIV+ Gay Men in Japan?
- ICAAC 2013: Treatment of HCV Genotypes 2/3 in HIV/HCV Coinfected People
- ICAAC 2013: Interferon Response Reduces Liver Disease and Death in HIV/HCV Coinfected
- ICAAC 2013: Novel Therapeutic Vaccine Reduces Genital Herpes Shedding
Web Design and Development by